Meta‐analysis: Risk of pancreatic cancer in patients with inflammatory bowel disease

Zamani, Mohammad; Alizadeh‐Tabari, Shaghayegh; Murad, Mohammad Hassan; Ananthakrishnan, Ashwin N.; Malekzadeh, Reza; Talley, Nicholas J.

doi:10.1111/apt.17919

Cited by 2 publications

(1 citation statement)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IBD may also be associated with metabolic conditions and can often develop extraintestinal manifestations, with an impact on different organs, such as the liver. For instance, it has recently been shown that non-alcoholic fatty liver disease was observed in IBD patients, with a two times higher risk compared to healthy subjects [3].…”

Section: Introductionmentioning

confidence: 99%

Adipokines as Possible Players in Inflammatory Bowel Disease: Electrophysiological Evaluation of Their Role in Causing Functional Gastrointestinal Alterations in Murine Tissue

Garella,

Palmieri,

Squecco

2024

Gastrointestinal Disorders

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a clinical condition of the gastrointestinal tract that has significant incidence in childhood. Major symptoms include abdominal pain, dyspepsia, delayed gastric emptying, anorexia, diarrhea and weight loss. IBD etiopathogenesis is multifactorial, with a proven involvement of cytokines. In this regard, cytokines like resistin and adiponectin produced by adipose tissue play a crucial role in inflammation. Particularly, resistin seems related to IBD severity and is considered a promising marker of disease occurrence and progression. Unraveling its mechanism of action and downstream effectors is mandatory when designing novel therapies. This preclinical study aims to further elucidate the action of resistin in causing functional gastrointestinal alterations, comparing it with the well-defined effect of adiponectin. To this end, we carried out electrophysiological analysis on murine gastric fundus. We found that resistin, similarly to adiponectin, increases smooth muscle cell (SMC) capacitance, indicative of cell surface remodeling, which is consistent with relaxation. However, contrary to adiponectin, resistin unalters membrane potential and inward Ca2+ entry and scarcely affects outward current, suggesting its inefficacy in markedly modifying electrical phenomena on the SMC membrane. This outcome, supporting the role of resistin in gastrointestinal distention, as observed in IBD, rules out a strikingly direct effect on SMCs.

show abstract

Section: Introductionmentioning

confidence: 99%

Adipokines as Possible Players in Inflammatory Bowel Disease: Electrophysiological Evaluation of Their Role in Causing Functional Gastrointestinal Alterations in Murine Tissue

Garella,

Palmieri,

Squecco

2024

Gastrointestinal Disorders

View full text Add to dashboard Cite

show abstract

Meta‐analysis: Risk of lymphoma in patients with inflammatory bowel disease in population‐based cohort studies

Zamani,

Alizadeh‐Tabari,

Murad

et al. 2024

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SummaryBackgroundThere are inconsistencies in the results of the studies investigating the association between inflammatory bowel disease (IBD) and lymphoma.AimsThe aim of this study is to systematically appraise the risk of lymphoma development in patients with IBD.MethodsWe searched Embase, PubMed and Scopus from inception to 30 April 2024 to identify population‐based cohort studies that evaluated the risk of lymphoma in patients with IBD in comparison with those without IBD. We carried out random‐effects meta‐analyses and estimated pooled relative risks (RRs) with 95% confidence intervals (CIs).ResultsWe identified 23 eligible studies reporting 2078 lymphoma events in 656,731 patients with IBD. Patients with IBD had 30% higher odds of lymphoma (RR = 1.30 [95% CI: 1.21–1.40]). The risk of developing both Hodgkin's lymphoma (nine studies, RR = 1.29 [95% CI: 1.06–1.53]) and non‐Hodgkin's lymphoma (16 studies, RR = 1.31 [95% CI: 1.20–1.42]) was increased in patients with IBD (p for interaction = 0.881). The increased risk of lymphoma was observed in both Crohn's disease (17 studies, RR = 1.54 [95% CI: 1.27–1.80]) and ulcerative colitis (20 studies, RR = 1.22 [95% CI: 1.09–1.35]) (p for interaction = 0.026). Meta‐regression demonstrated that mean age of patients, study year, mean study follow‐up duration, and percentages of immunomodulators and biologics use did not influence study outcome.ConclusionsThe risk of lymphoma is only modestly increased in patients with IBD, with Crohn's disease having a slightly higher risk than ulcerative colitis. In IBD, there appears to be no difference between the risks of Hodgkin's and non‐Hodgkin's lymphoma.

show abstract

Meta‐analysis: Risk of pancreatic cancer in patients with inflammatory bowel disease

Cited by 2 publications

References 47 publications

Adipokines as Possible Players in Inflammatory Bowel Disease: Electrophysiological Evaluation of Their Role in Causing Functional Gastrointestinal Alterations in Murine Tissue

Adipokines as Possible Players in Inflammatory Bowel Disease: Electrophysiological Evaluation of Their Role in Causing Functional Gastrointestinal Alterations in Murine Tissue

Meta‐analysis: Risk of lymphoma in patients with inflammatory bowel disease in population‐based cohort studies

Contact Info

Product

Resources

About